Here is the patent application following your outline precisely:

# DESCRIPTION  

## RELATED APPLICATION DATA  

The present application claims priority to U.S. Provisional Patent Application No. 62/XXXXXX, filed on [DATE], entitled "[TITLE]", the entire contents of which are incorporated herein by reference.  

## STATEMENT OF GOVERNMENT INTERESTS  

This invention was made with government support under Grant No. [GRANT NUMBER] awarded by [AGENCY NAME]. The government has certain rights in the invention.  

## FIELD  

The present invention relates generally to methods of producing proteins containing non-standard amino acids (NSAAs). More particularly, the invention provides systems and methods for post-translational proofreading to improve the fidelity of NSAA incorporation into target polypeptides.  

## BACKGROUND  

Proteins are typically composed of 20 standard amino acids (SAAs) that are incorporated during translation according to the genetic code. While this limited repertoire suffices for most biological functions, the ability to incorporate NSAAs - amino acids not among the 20 SAAs - enables expansion of protein functionality for research, therapeutic, and industrial applications.  

Several challenges limit efficient NSAA incorporation. First, orthogonal translation systems (OTS) that incorporate NSAAs often exhibit promiscuity, mistakenly incorporating SAAs when the desired NSAA is unavailable. Second, methods for assessing NSAA incorporation fidelity are labor-intensive and lack throughput. Third, even when NSAAs are successfully incorporated, competing incorporation of SAAs reduces the yield of desired NSAA-containing proteins.  

Current approaches to NSAA incorporation rely primarily on pre-translational quality control through engineering of aminoacyl-tRNA synthetases (aaRS) and tRNAs. While these methods have enabled NSAA incorporation, they fail to address misincorporation events that occur despite optimized OTS components. There remains an unmet need for post-translational quality control mechanisms that can discriminate between properly and improperly incorporated amino acids in target proteins.  

The N-end rule pathway, a conserved protein degradation system, recognizes specific N-terminal amino acids as degradation signals. In Escherichia coli, the ClpS adapter protein binds proteins bearing N-terminal aromatic (Tyr, Phe, Trp) or large hydrophobic (Leu) residues and targets them for degradation by the ClpAP protease complex. While this natural system degrades proteins with certain N-terminal SAAs, it lacks the ability to distinguish between desired NSAAs and undesired SAAs or misincorporated NSAAs.  

## SUMMARY  

The present invention provides methods for producing target polypeptides containing desired NSAAs with improved fidelity through post-translational proofreading (PTP). The methods employ the N-end rule pathway of protein degradation to selectively degrade polypeptides containing undesired amino acids while preserving those containing desired NSAAs.  

In one aspect, the invention provides a method comprising: (a) providing a cell genetically modified to express: (i) a target polypeptide having an amino acid target location where NSAA incorporation is desired; (ii) an orthogonal aminoacyl-tRNA synthetase (aaRS)/tRNA pair cognate to the desired NSAA; (iii) a removable protecting group positioned to protect the amino acid target location from exposure as an N-terminal residue; and (iv) a protease system comprising an adapter protein and corresponding protease capable of degrading the target polypeptide based on its N-terminal amino acid; (b) culturing the cell under conditions permitting expression of the target polypeptide, wherein the target polypeptide is produced with either: (i) the desired NSAA at the amino acid target location, or (ii) an undesired amino acid at the amino acid target location; (c) removing the protecting group to expose the amino acid at the target location as the N-terminal residue of the target polypeptide; and (d) degrading target polypeptides having undesired N-terminal amino acids via the protease system while preserving target polypeptides having desired N-terminal NSAAs.  

The removable protecting group may be ubiquitin or another cleavable protein domain. The protease system may comprise ClpS adapter protein and ClpAP protease. The method may further comprise engineering the adapter protein to alter its recognition specificity for particular NSAAs or SAAs.  

In another aspect, the invention provides genetically modified cells comprising: (a) nucleic acids encoding a target polypeptide having a protecting group and an NSAA incorporation site; (b) an orthogonal aaRS/tRNA pair for incorporating a desired NSAA; (c) enzymes for removing the protecting group to expose the NSAA incorporation site as the N-terminus; and (d) components of the N-end rule pathway for degrading target polypeptides based on their N-terminal amino acid.  

The methods and systems of the invention enable high-fidelity production of NSAA-containing proteins, improved evolution of orthogonal translation systems, and enhanced biocontainment strategies.  

## DETAILED DESCRIPTION  

The following detailed description illustrates embodiments of the invention by way of example and not by way of limitation.  

### I. Definitions and Components  

As used herein, "polypeptide" and "protein" refer to polymers of amino acids of any length, including modified, naturally occurring, and synthetic amino acids. A "target polypeptide" is a polypeptide of interest that is to be produced with one or more NSAAs incorporated at specific locations.  

"Non-standard amino acids" (NSAAs) are amino acids not among the 20 standard amino acids encoded by the universal genetic code. NSAAs include but are not limited to: p-acetyl-phenylalanine (pAcF), p-azido-phenylalanine (pAzF), biphenylalanine (BipA), p-iodo-phenylalanine, p-bromophenylalanine, and 5-hydroxytryptophan (5OHW).  

An "orthogonal translation system" (OTS) comprises an orthogonal aminoacyl-tRNA synthetase (aaRS) and its cognate tRNA that function in a host cell without cross-reacting with the host's native translation machinery. The OTS incorporates NSAAs in response to a designated codon, typically the amber stop codon (UAG).  

The "N-end rule pathway" is a conserved proteolytic system that degrades proteins based on their N-terminal amino acids. In E. coli, the pathway involves the ClpS adapter protein that recognizes specific N-terminal residues (Tyr, Phe, Trp, Leu) and delivers the tagged proteins to the ClpAP protease for degradation.  

### II. Removable Protecting Groups  

The invention employs removable protecting groups to shield the amino acid at the target location from exposure as an N-terminal residue until desired. Suitable protecting groups include:  

Ubiquitin and ubiquitin-like proteins that can be cleaved by specific proteases. In prokaryotic systems, ubiquitin can be cleaved by ubiquitin-specific proteases such as UBP1 from Saccharomyces cerevisiae.  

Self-splicing protein domains such as inteins that autocatalytically excise themselves from the polypeptide chain.  

Specific peptide sequences cleavable by proteases such as TEV protease, Factor Xa, or thrombin. For example, the sequence MENLYFQ/* serves as a cleavage site for TEV protease in eukaryotic systems.  

Methionine aminopeptidases can remove N-terminal methionine residues, exposing the adjacent amino acid as the new N-terminus.  

### III. Detectable Moieties  

Target polypeptides may include detectable moieties to facilitate monitoring of NSAA incorporation. Suitable moieties include:  

Fluorescent proteins such as green fluorescent protein (GFP) or its variants (e.g., sfGFP) fused to the C-terminus of the target polypeptide.  

Epitope tags such as His-tags, FLAG-tags, or HA-tags that enable detection via antibodies.  

Enzymatic reporters like β-galactosidase or luciferase that produce detectable signals.  

### IV. Genetic Modifications  

Cells are genetically modified to include:  

Foreign nucleic acids encoding the target polypeptide with its protecting group and NSAA incorporation site.  

Genes for the orthogonal aaRS and tRNA pair specific for the desired NSAA.  

Nucleic acids encoding enzymes for removing the protecting group (e.g., UBP1).  

Components of the N-end rule pathway (e.g., ClpS, ClpAP).  

These nucleic acids may be introduced via plasmids, viral vectors, or genomic integration. Suitable vectors include pEVOL for OTS components and pZE21 for reporter constructs. Regulatory elements (promoters, ribosome binding sites, terminators) control expression of these components.  

### V. Adapter Protein Protease Systems  

The protease system comprises an adapter protein that recognizes specific N-terminal amino acids and delivers the tagged proteins to a protease for degradation. In E. coli:  

The ClpS adapter recognizes N-terminal Tyr, Phe, Trp, and Leu.  

ClpAP protease degrades proteins delivered by ClpS.  

The system can be engineered by modifying ClpS to alter its recognition specificity. For example, the ClpS V65I variant stabilizes proteins with various NSAAs while maintaining degradation of proteins with SAAs.  

### VI. Cells  

The methods can be practiced in:  

Prokaryotic cells such as Escherichia coli, Bacillus subtilis, or other bacteria.  

Eukaryotic cells including yeast (Saccharomyces cerevisiae), mammalian, plant, or fungal cells.  

Genomically recoded organisms (GROs) like E. coli strain C321.ΔA that lack amber stop codons and release factor 1, improving NSAA incorporation efficiency.  

### VII. Standard Amino Acids  

Standard amino acids are the 20 amino acids encoded by the universal genetic code. The N-end rule in E. coli naturally recognizes Tyr, Phe, Trp, and Leu as destabilizing. Engineering can expand this recognition:  

Isoleucine and Valine can be made destabilizing by engineering ClpS.  

Aspartate and Glutamate can be made destabilizing by expressing bacterial aminoacyl-transferase Bpt.  

Asparagine and Glutamine can be made destabilizing by engineering the N-end rule pathway.  

### VIII. Non-Standard Amino Acids  

NSAAs expand protein functionality. Examples include:  

Aromatic NSAAs: pAcF, pAzF, BipA, p-iodo-phenylalanine.  

Tryptophan analogs: 5OHW.  

Commercially available NSAAs with diverse chemical properties.  

Each NSAA requires a cognate orthogonal aaRS/tRNA pair for incorporation.  

## Exemplary Degradation Materials and Methods  

An exemplary method comprises:  

1. Providing an E. coli cell genomically recoded to eliminate UAG codons.  
2. Introducing nucleic acids encoding:  
   - A target polypeptide (Ub-X-sfGFP) with a UAG codon at the NSAA incorporation site  
   - BipARS and tRNACUATyr for BipA incorporation  
   - UBP1 ubiquitin cleavase  
   - ClpS adapter protein  
3. Culturing cells with and without BipA.  
4. Inducing UBP1 expression to cleave ubiquitin, exposing the incorporated amino acid as the N-terminus.  
5. Degrading proteins with undesired N-terminal amino acids via ClpS/ClpAP while preserving proteins with BipA.  
6. Monitoring sfGFP fluorescence as a measure of successful BipA incorporation.  

## Example II  

### A Method of Making a Protein Having a Non-Standard Amino Acid Incorporated at its N-Terminus in an Engineered E. coli Having Orthogonal Translation Systems by Engineering Post-Translational Proofreading to Discriminate Non-Standard Amino Acids  

We implemented post-translational proofreading (PTP) in E. coli strain C321.ΔA genomically recoded to lack UAG codons. The strain was further modified to genomically integrate a reporter construct comprising ubiquitin, a UAG codon, and sfGFP.  

Plasmids were introduced expressing:  
- BipARS and tRNACUATyr for BipA incorporation  
- UBP1 ubiquitin cleavase  
- ClpS adapter protein  

When UBP1 cleaved ubiquitin, the amino acid incorporated at the UAG site became the N-terminus. Wild-type ClpS mediated degradation when Tyr, Phe, Trp, or Leu were incorporated instead of BipA.  

We engineered ClpS variants with altered specificities. ClpS V65I stabilized proteins with various NSAAs while maintaining degradation of proteins with SAAs. This variant improved discrimination between desired NSAAs and undesired SAAs.  

## Example III  

We rationally engineered ClpS variants with tunable specificities. ClpS L32F destabilized proteins with most NSAAs except the largest (p-iodo-phenylalanine and larger). These engineered variants enable custom tailoring of the N-end rule pathway for specific NSAAs.  

## Example IV  

We applied PTP to sense codon reassignment, where a standard codon is globally reassigned to an NSAA. PTP enabled discrimination between successful NSAA incorporation and misincorporation of SAAs at reassigned codons.  

## Example V  

Detailed strain engineering involved:  

1. Genomic integration of TET promoter and Ub-UAG-sfGFP in E. coli C321.ΔA using λ Red recombineering.  
2. MAGE to inactivate mutS and clpS genes.  
3. Construction of UBP1/clpS_V65I operon via Gibson assembly.  
4. Introduction of orthogonal aaRS/tRNA pairs from pEVOL plasmids.  

Culture conditions were optimized for PTP experiments in 2XYT medium to maintain cell growth during ClpS overexpression.  

## Example VI  

A general method for making target polypeptides with NSAAs comprises:  

1. Genetically modifying a cell to express:  
   - Target polypeptide with protecting group and NSAA site  
   - Orthogonal aaRS/tRNA pair  
   - UBP1 cleavase  
   - ClpS/ClpAP degradation system  
2. Culturing cells with desired NSAA.  
3. Inducing UBP1 to cleave protecting group, exposing NSAA site as N-terminus.  
4. Degrading polypeptides with undesired N-terminal amino acids.  
5. Isculating polypeptides with desired NSAAs.  

This method improves NSAA incorporation fidelity for research, therapeutic, and industrial applications.  

The complete patent application has been provided following the outline precisely while incorporating all key elements from the research paper. Each section has been developed with appropriate detail using formal patent language while maintaining the required structure.